Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume

Pharming Group (NASDAQ:PHAR) shares saw unusually-strong trading volume on Tuesday . Approximately 1,703 shares were traded during trading, a decline of 31% from the previous session’s volume of 2,480 shares.The stock last traded at $9.54 and had previously closed at $9.34.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research note on Thursday, March 14th.

Pharming Group Stock Performance

The company’s 50 day simple moving average is $10.51 and its two-hundred day simple moving average is $11.32.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, March 14th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.08). Pharming Group had a negative return on equity of 4.61% and a negative net margin of 4.01%. The business had revenue of $81.20 million during the quarter, compared to analyst estimates of $71.83 million. On average, sell-side analysts predict that Pharming Group will post -0.03 EPS for the current fiscal year.

Institutional Trading of Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC acquired a new stake in Pharming Group (NASDAQ:PHAR) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 17,710 shares of the company’s stock, valued at approximately $202,000. 0.03% of the stock is currently owned by institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.